RxDoctor Payments Data

Amy Olsen

Family · Vernal, UTNPI 1598991275

Payments from drug & device makers

$1,407in general payments, 2019–2025

Across 76 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$422
  • Lilly USA, LLC$181
  • Corcept Therapeutics$117
  • Amgen$117
  • Boehringer Ingelheim$70
  • Globus Medical$70
  • plus $430 from 16 others

What the payments were for

  • Food & beverage$1,407100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,407 in reported general payments places this provider in the 75th percentile of 1,460 family providers in Utah.

See all family providers in Utah

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$14,266
Nabumetone18$925
Levothyroxine Sodium117$910
SynthroidLevothyroxine Sodium11$815
Duloxetine Hcl22$755
Atorvastatin Calcium69$708
Estradiol (Once Weekly)Estradiol13$619
Gabapentin28$503
Albuterol Sulfate HfaAlbuterol Sulfate15$319
Omeprazole42$304
ProgesteroneProgesterone, Micronized14$288
Losartan Potassium34$254
Lisinopril46$218
Fluticasone Propionate17$194
Metformin Hcl29$157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$66$14,26617 claims
AbbVieSynthroid$35$81511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,460 family providers in Utah.

Other family in Vernal

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →